MarketWatch·· 6 天前AI 评分27
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
利空-0.25对 相关行业影响 轻微
监管指控可能引发涉事生物医药股票波动
stock_ai_django 新闻打标（gpt-6-luna），方向针对资产价格，不是本站判断，也不构成投资建议
AI 导读
The Federal Trade Commission and seven states say Shkreli should be held in contempt
来源：MarketWatch · marketwatch.com